This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
CU-2010 and CU-2020 are synthetic compounds that act as serine protease inhibitors. These were developed in 2010 to replace the use of aprotinin during and after cardiac surgery, including surgeries with cardiopulmonary bypass which cause blood loss and hemorrhagic complications. CU-2010 and CU-2020 were developed to avoid many issues associated with the use of aprotinin, including the risk of an allergic reaction and infection. Since the isolation of aprotinin is expensive, a drug with a simpler synthesis was desired.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is foaf:primaryTopic of |